Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 12

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 12
---
 (88%) versus placebo
(58%) (p = 0.047). At TOC for BAT and at EOS, 100% of the AP-SA02 treated subjects had clinically responded (p = 0.017) versus 25% of
placebo subjects considered non-responsive due to either relapse or treatment failure, consistent with the non-responder rate reported
in the literature for recent phase 3 trials. Of note, the clinical response with AP-SA02 occurred regardless of whether subjects were
infected with methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). All subjects infected with
MRSA and treated with AP-SA02 and BAT cleared their infection by TOC for BAT with no evidence of relapse through EOS, as compared to
the relapse rate of BAT alone as noted above. Supporting the investigator assessment, clinical outcome was assessed by the CEAC, who
agreed that subjects who received placebo had a 22% and 25% non-responder rate at TOC with BAT and at EOS, respectively, while 100% of
the subjects who received AP-SA02 clinically responded (p = 0.025: TOC BAT; p = 0.020: EOS).

<div align='center'>4</div>

Additionally,
faster time to a negative blood culture and decline of key predictors of mortality and complications in SAB, including interleukin-10
and C-reactive protein, support the improved responder rates in subjects treated with AP-SA02.

We previously demonstrated
the persistence of AP-SA02 in the IV space on multiple days one hour post IV push. These trial results support AP-SA02 homing to different
sites of infection, presumably penetrating biofilms, and infecting and lysing the target S. aureus bacteria, independent of antibiotic
resistance patterns and site of infection.

The results from our Phase
1b/2a diSArm study are an important step forward in our effort to confirm the potent antimicrobial activity of phage therapy and the
completion of the study represents a significant milestone in the development of AP-SA02, moving us one step closer to introducing an
effective new treatment option to patients suffering from complicated S. aureus bacteremia. This is the first clear evidence in
a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity
and mortality in the United States.

Findings from the